Search

Objective: To observe the efficacy and safety of Eribulin⁃based regimen in patients with HER2 negative metastatic breast cancer in the real world. Methods: We retrospectively analyzed clinical data of 60 patients with HER2⁃negative metastatic breast cancer who received Eribulin⁃based therapy in Jiangsu Province Hospital between January 2020 and November 2021. Results: 30% of patients received Eribulin monotherapy while 70% of patients received Eribulin⁃based combination therapy. After a median follow⁃up of 5 months, the median progression⁃free survival (PFS) was 4.30 months (95%CI: 3.86⁃5.69 months), Median overall survival (OS) was not reached. The overall response rate (ORR) was 25.00%, and disease control rate (DCR) was 76.67%. Log⁃rank univariate analysis showed that there was a statistically significant difference between Eribulin monotherapy versus Eribulin⁃based combination regimen (2.93 months vs. 4.7 months, P=0.042) . Multivariate analysis indicated that age and chemotherapy lines were independent risk factors for PFS in patients with HER2⁃negative metastatic breast cancer treated with Eribulin (P=0.022, 0.048) . The most common grade Ⅲ⁃Ⅳ adverse events (AE) associated with Eribulin include neutropenia, leukopenia, anemia, and lymphopenia, and no treatment⁃ related severe adverse event (SAE) or deaths were observed. Conclusion: Our research indicated that Eribulin⁃based regimen can effectively treat HER2⁃negative metastatic breast cancer with controllable side effects. [ABSTRACT FROM AUTHOR]